Gastrointestinal Endoscopy
Volume 72, Issue 6 , Pages 1303-1307 , December 2010

A case of early Barrett's adenocarcinoma repeatedly developing multiple metachronous lesions shortly after endoscopic therapy: an analysis for genetic and epigenetic alterations

References 

  1. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology. 2000;119:333–338
  2. Wang KK, Sampliner RE Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103:788–797
  3. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut. 2006;55:442
  4. Das KM, Prasad I, Garla S, et al. Detection of a shared colon epithelial epitope on Barrett epithelium by a novel monoclonal antibody. Ann Intern Med. 1994;120:753–756
  5. Griffel LH, Amenta PS, Das KM. Use of a novel monoclonal antibody in diagnosis of Barrett's esophagus. Dig Dis Sci. 2000;45:40–48
  6. Moriichi K, Watari J, Das KM, et al. Effects of Helicobacter pylori infection on genetic instability, the aberrant CpG island methylation status and the cellular phenotype in Barrett's esophagus in a Japanese population. Int J Cancer. 2009;124:1263–1269
  7. Watari J, Moriichi K, Tanabe H, et al. Differences in genetic instability and cellular phenotype among Barrett's, cardiac, and gastric intestinal metaplasia in a Japanese population with Helicobacter pylori. Histopathology. 2009;55:261–269
  8. Boland CR, Thibodeau SN, Hamilton SR, et al. National Cancer Institute on Workshop on Microsatellite instability for Cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5257
  9. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc. 2007;65:3–10
  10. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008;57:1200–1206
  11. Chennat J, Konda VJ, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma—an American single-center experience. Am J Gastroenterol. 2009;104:2684–2692
  12. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288
  13. Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010;8:23–29
  14. Aldulaimi D, Jankowski J. Barrett's esophagus: an overview of the molecular biology. Dis Esophagus. 1999;12:177–180
  15. Brito MJ, Filipe MI, Linehan J, et al. Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. Int J Cancer. 1995;60:27–32
  16. Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol. 2009;104:816–824
  17. Wang JS, Guo M, Montgomery EA, et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol. 2009;104:2153–2160

PII: S0016-5107(10)01663-9

doi: 10.1016/j.gie.2010.05.018

Gastrointestinal Endoscopy
Volume 72, Issue 6 , Pages 1303-1307 , December 2010

Article Tools

* Image Usage & Resolution